Monobodies are synthetic binding proteins constructed using a fibronectin type III domain as a molecular scaffold. Monobodies are robust alternative to antibodies to create target-binding proteins. Moreover, the monobody based drug discovery program has experienced a surge in clinical trials and enrollments for drugs in different indications worldwide. Monobody based therapeutics are fast becoming recognized in the clinical trials arena. In the recent past, the use of these drugs has been increasing in diverse clinical trial programs. Furthermore, the overall demand for this therapeutic category is steadily increasing, to address serious medical issues or conditions. Genetically encoded monobodies are effective ‘tool biologics’ for validating intracellular targets. These drugs hold significant potential to improve human health.
Get FREE Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/43
Major players operating in the global monobody based therapeutic drugs market are Eli Lilly and Company, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Sanofi, Pfizer Inc., Biogen, Inc., Amgen, Merck & Co., Novo Nordisk A/S, and Baxter International Inc., among others.
Key Market Drivers:
Increasing prevalence of cancer around the world is expected to propel growth of the monobody based therapeutic drugs market during the forecast period. Monobodies have great potential in the treatment of cancer. For instance, according to the World Health Organization (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Around 70% of deaths from cancer occur in low- and middle-income countries. Thus, there is an increasing demand for safe and effective therapeutic drugs to treat various types of cancer.
Moreover, increase in rate of organ transplantation and significant investment in development of novel therapeutics is expected to augment the growth of the monobody based therapeutic drugs market. Monoclonal antibodies are used in successful transplant and are administered before transplant. For instance, according to the Health Resources and Services Administration, agency of the U.S. Department of Health and Human Services, over 106,873 number of men, women, and children on the national transplant waiting list, and over 39,000 transplants were performed in 2020.
COVID-19 Impact Analysis:
SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). The monoclonal antibody cocktail can be used to treat mild to moderate ‘high risk’ patients with COVID-19. These antibody are used to treat mild to moderate COVID-19 patients who are at high risk for progression to severe disease and/or hospitalization. Currently, three anti-SARS-CoV-2 mAb products have received Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 patients. For instance, in May 2021, Cipla launched Roche’s antibody cocktail (Casrivimab and Imdevimab) in India. The antibody cocktail is to be administered for the treatment of mild to moderate Covid-19 in adults and pediatric patients. This in turn is expected to boost the market growth.
Get PDF Brochure with Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/43
The monobody based therapeutic drugs market is expected to exhibit a CAGR of XX % during the forecast period due to the outbreak of COVID-19 around the world. For instance, in November 2020, the U.S. Food and Drug Administration (USFDA) issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
Among regions, North America and Asia Pacific are expected to witness robust growth in the monobody based therapeutic drugs market due to the increasing prevalence of cancer, advancement in monobody technology, and significant investment in development of novel therapeutics in these regions. For instance, according to the American Cancer Society, in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Moreover, according to WHO/Europe, Europe comprises only one eighth of the total world population but has around one quarter of the global total of cancer cases with some 3.7 million new patients per year.
Reasons to Purchase this Report
• Current and future of global Monobody Based Therapeutic Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Monobody Based Therapeutic Drugs Market Size Analysis
11.6 COVID-19 Outbreak: Monobody Based Therapeutic Drugs Industry Impact
Chapter 2 Global Monobody Based Therapeutic Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Monobody Based Therapeutic Drugs (Volume and Value) by Type
2.3 Global Monobody Based Therapeutic Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Monobody Based Therapeutic Drugs Sales, Consumption, Export, Import by Regions
Chapter 5 North America Monobody Based Therapeutic Drugs Market Analysis
Chapter 6 East Asia Monobody Based Therapeutic Drugs Market Analysis
Chapter 7 Europe Monobody Based Therapeutic Drugs Market Analysis
Chapter 8 South Asia Monobody Based Therapeutic Drugs Market Analysis
Chapter 9 Southeast Asia Monobody Based Therapeutic Drugs Market Analysis
Chapter 10 Middle East Monobody Based Therapeutic Drugs Market Analysis
Chapter 11 Africa Monobody Based Therapeutic Drugs Market Analysis
Chapter 12 Oceania Monobody Based Therapeutic Drugs Market Analysis
Chapter 13 South America Monobody Based Therapeutic Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Monobody Based Therapeutic Drugs Business
Chapter 15 Global Monobody Based Therapeutic Drugs Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027